Is Traws Pharma, Inc. (TRAW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 166.9% / 30% | 13.8% / 30% | 62660.62% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 166.9% / 33% | 13.8% / 33% | 62660.62% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 85.5% / 33% | 7.1% / 33% | 62660.62% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 166.9% / 33% | 13.8% / 33% | 62660.62% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 85.5% / 33% | 7.1% / 50% | 62660.62% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -554.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -1059.6% | |
| Return on Assets (ROA) | -92.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$30M |
| Free Cash Flow | -$30M |
| Current Ratio | 1.2 |
| Total Assets | $25M |
Price & Trading
| Last Close | $1.93 |
| 50-Day MA | $1.97 |
| 200-Day MA | $1.89 |
| Avg Volume | 205K |
| Beta | 1.8 |
|
52-Week Range
$0.97
| |
About Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Traws Pharma, Inc. (TRAW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Traws Pharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Traws Pharma, Inc.'s debt ratio?
Traws Pharma, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Traws Pharma, Inc.'s key financial metrics?
Traws Pharma, Inc. has a market capitalization of $14M, and revenue of $226,000. Return on equity stands at -1059.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.